secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013391
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026
--------------------------------------------------------------------------------

- Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.
- Presentation (#3539, board K692) focuses on tissue concentration-driven effects beyond traditional plasma pharmacokinetics.
- Data aims to inform improved delivery strategies for mTOR inhibitors, including IV and nanoparticle formulations.
- Oncotelic (OTLC) holds minority stake in Sapu Nano; no financial terms or guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226013391/0001493152-26-013391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226013391/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer